Keymed Biosciences Inc.

2162

KYG5252B1023

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 02:02:31 2024-04-24 am EDT			5-day change	1st Jan Change
33.9 ^HKD	+4.95%		+14.12%	-30.86%

Apr. 12	Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	MT
Mar. 27	KeyMed Biosciences’ Attributable Loss Widens in 2023	MT

Keymed Biosciences Inc.(SEHK:2162) added to S&P Global BMI Index

December 20, 2021 at 12:00 am EST

Latest news about Keymed Biosciences Inc.

Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	Apr. 11	MT
KeyMed Biosciences’ Attributable Loss Widens in 2023	Mar. 27	MT
Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Keymed Biosciences Buys Back Shares	Jan. 22	MT
Keymed's Rhinosinusitis Treatment Achieves Primary Endpoints; Shares Rise 5%	Dec. 27	MT
Keymed Biosciences Inc. Announces Phase III Clinical Trial of Cm310 for the Treatment of Chronic Rhinosinusitis with Nasal Polyps	Dec. 26	CI
China Accepts New Drug Application for Keymed Biosciences' Atopic Dermatitis Injection; Shares Rise 4%	Dec. 07	MT
Keymed Biosciences Inc. Announces New Drug Application of Stapokibart Injection	Dec. 06	CI
Keymed Presents Phase 1 Trial Data for Gastric/Gastroesophageal Cancer Drug	Nov. 08	MT
Keymed Biosciences Inc. Announces the Latest Data from a Phase I Clinical Study of CMG901	Nov. 07	CI
Keymed Biosciences Inc. Announces CM310 Phase III Clinical Trial Topline Data Accepted for Poster Presentation at the European Academy of Dermatology and Venereology Congress 2023	23-10-11	CI
Keymed Biosciences’ Profit Surges in H1	23-08-25	MT
Keymed Biosciences Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Keymed Biosciences to Acquire 18.7% of Kangnuo Xing for 150.6 Million Yuan	23-06-27	MT
Keymed Presents Data on Phase 1 Study for Lymphoma, Myeloma Drug; Shares Fall 4%	23-06-11	MT
Keymed Biosciences Inc. Announces Latest Data from the Phase I Clinical Study of CM313	23-06-11	CI
Keymed Biosciences Completes Data Unblinding for Phase 3 Study of Eczema Treatment; Shares Rise 8%	23-05-29	MT
Keymed Biosciences Inc. Announces Latest Development on Phase III Clinical Trial of CM310 for the Treatment of Moderate to Severe Atopic Dermatitis in Adults	23-05-29	CI
Keymed Biosciences Inc. Announces Board and Committee Changes	23-04-17	CI
Stocks add to rebound; SSE ups earnings guidance	23-03-30	AN
AstraZeneca Completes KYM Solid Tumors Treatment Deal	23-03-30	DJ
Keymed Biosciences Inc. Announces Phase III Confirmatory Clinical Study of Its Self-Developed Class 1 Innovative Drug CM310 Recombinant Humanized Monoclonal Antibody Injection	23-03-28	CI
Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05	23-02-23	CI
Keymed and Lepu Biopharma Jointly Announces Global Exclusive Licence Agreement with Astrazeneca for Cmg901	23-02-23	CI

Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company's main products include CM310, CM326 and CMG901.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Keymed Biosciences Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

29.86 CNY

Average target price

54.48 CNY

Spread / Average Target

+82.42%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
KEYMED BIOSCIENCES INC.	-30.86%	1.14B
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+1.66%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-6.82%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs